These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37069240)

  • 1. IKKα inhibition re-sensitizes acquired adriamycin-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
    Liao J; Qin QH; Lv FY; Huang Z; Lian B; Wei CY; Mo QG; Tan QX
    Sci Rep; 2023 Apr; 13(1):6211. PubMed ID: 37069240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells
    Alsawalha L; Ahram M; Abdullah MS; Dalmizrak O
    Anticancer Agents Med Chem; 2022; 22(17):3038-3048. PubMed ID: 35579133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin.
    Bednarski BK; Ding X; Coombe K; Baldwin AS; Kim HJ
    Mol Cancer Ther; 2008 Jul; 7(7):1827-35. PubMed ID: 18644995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CENPF knockdown inhibits adriamycin chemoresistance in triple-negative breast cancer via the Rb-E2F1 axis.
    Wang D; Xu W; Huang M; Ma W; Liu Y; Zhou X; Yang Q; Mu K
    Sci Rep; 2023 Jan; 13(1):1803. PubMed ID: 36720923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
    Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
    Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
    Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
    Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
    Salaroglio IC; Gazzano E; Abdullrahman A; Mungo E; Castella B; Abd-Elrahman GEFA; Massaia M; Donadelli M; Rubinstein M; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2018 Nov; 37(1):286. PubMed ID: 30482226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
    Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
    Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.
    Das CK; Linder B; Bonn F; Rothweiler F; Dikic I; Michaelis M; Cinatl J; Mandal M; Kögel D
    Neoplasia; 2018 Mar; 20(3):263-279. PubMed ID: 29462756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.
    Wen J; Yeo S; Wang C; Chen S; Sun S; Haas MA; Tu W; Jin F; Guan JL
    Breast Cancer Res Treat; 2015 Feb; 149(3):619-29. PubMed ID: 25638397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ST8SIA1 inhibition sensitizes triple negative breast cancer to chemotherapy via suppressing Wnt/β-catenin and FAK/Akt/mTOR.
    Wan H; Li Z; Wang H; Cai F; Wang L
    Clin Transl Oncol; 2021 Apr; 23(4):902-910. PubMed ID: 32939659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
    Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
    Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability.
    Sirois I; Aguilar-Mahecha A; Lafleur J; Fowler E; Vu V; Scriver M; Buchanan M; Chabot C; Ramanathan A; Balachandran B; Légaré S; Przybytkowski E; Lan C; Krzemien U; Cavallone L; Aleynikova O; Ferrario C; Guilbert MC; Benlimame N; Saad A; Alaoui-Jamali M; Saragovi HU; Josephy S; O'Flanagan C; Hursting SD; Richard VR; Zahedi RP; Borchers CH; Bareke E; Nabavi S; Tonellato P; Roy JA; Robidoux A; Marcus EA; Mihalcioiu C; Majewski J; Basik M
    Mol Cancer Res; 2019 Dec; 17(12):2492-2507. PubMed ID: 31537618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
    Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
    Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
    Byerly JH; Port ER; Irie HY
    Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
    Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
    Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. USP37 downregulation elevates the Chemical Sensitivity of Human Breast Cancer Cells to Adriamycin.
    Qin T; Cui XY; Xiu H; Huang C; Sun ZN; Xu XM; Li LH; Yue L
    Int J Med Sci; 2021; 18(2):325-334. PubMed ID: 33390801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.